An alternative route to pertussis protection?

[...]the relative efficacy of BPZE1 versus Tdap against clinical pertussis is unclear, because no antibody correlate of protection has been established. [...]we agree with the authors' assessment that BPZE1 could help to avert B pertussis infections, and could lead to reduced transmission and d...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) 2023-03, Vol.401 (10379), p.800-801
Main Authors: Edwards, Kathryn M, Decker, Michael D
Format: Article
Language:English
Subjects:
Administration, Intranasal
Antibodies
Antigens
Babies
Diphtheria
Disease control
Durability
Epidemics
Humans
Immune response
Immune response (humoral)
Infections
Pertussis
Pertussis Vaccine
Pharmaceuticals
Prevention
Safety
Tetanus
Vaccines
Whooping cough
Whooping Cough - prevention & control
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[...]the relative efficacy of BPZE1 versus Tdap against clinical pertussis is unclear, because no antibody correlate of protection has been established. [...]we agree with the authors' assessment that BPZE1 could help to avert B pertussis infections, and could lead to reduced transmission and diminished epidemic cycles, but more studies are required to ensure the durability of the immune response and to establish whether BPZE1's less robust humoral response impairs the vaccine's disease prevention. KME has received grants from the US National Institutes of Health (mentoring young investigators) and the Centers for Disease Control and Prevention (assessing vaccine safety), has consulted for Bionet and IBM, and has served on data safety and monitoring boards for Sanofi, X-4 Pharma, Seqirus, Moderna, Pfizer, Merck, and Roche.
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(23)00225-8